Project Grant R43DK123901

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a novel therapeutic antibody as a first-in-class treatment for acromegaly. Acromegaly is a rare endocrine disorder affecting approximately 21,000 adults in the U.S. and is associated with serious health complications and increased mortality. The $1,035,589 award...

This $2,845,159 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund the establishment of the National Biorepository and Resource for Pituitary Neuroendocrine Tumor Translational Research (BIOPITNET). The key objectives are to: Create a centralized biorepository of pituitary neuroendocrine tumor (PITNET) tissue samples and resources benchmarked...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program, provides $999,615.00 to Extend Biosciences Inc. to develop a long-acting parathyroid hormone (PTH) derivative called EXT608 for the treatment of hypoparathyroidism. Hypoparathyroidism is a rare disease resulting from insufficient PTH, leading to metabolic issues like hypocalcemia. While current...

This $149,008 Cooperative Agreement awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Trans-NIH Research Support program (CFDA 93.310) is funding Cartesian Therapeutics Inc. to conduct a Phase 2 clinical study of its Descartes-08 RNA-engineered chimeric antigen receptor (CAR) T cell therapy. The goal is to evaluate the safety, efficacy, and durability of Descartes-08 in treating systemic lupus erythematosus (SLE), an autoimmune disease impacting over 3...

This Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $1,418,424 to Tigatx Inc., a small business based in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, such as non-small cell lung cancer (NSCLC). The funding will enable Tigatx to progress TIGA-001 through CMC activities, in vitro pharmacology studies, and...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business in Seattle, WA. The funding supports research to develop an immunoglobulin G (IgG) protease enzyme as a novel therapeutic for treating immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. Key objectives include engineering the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $293,680 to Antiger Therapeutics Inc. to develop targeted immunotherapies for celiac disease (CD). The primary objective is to generate a biologic that blocks the pathogenic T cells recognizing the gluten peptide-DQ2 complex, a key factor in the autoimmune response underlying CD. Specifically, the award will fund the...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA# 93.350, provides $350,000 to Adiutrix Therapeutics LLC to develop novel anti-fibrotic compounds targeting the collagen prolyl-4 hydroxylase (C-P4H) enzyme. The goal is to identify and validate first-in-class therapeutics to treat underserved fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma, chronic kidney disease, and Crohn's disease. The Phase I project aims to develop...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into a bifunctional IgE antagonist and dissociator (ANDI) drug candidate. The goal is to develop an innovative treatment that can both antagonize and dissociate IgE receptor-bound on mast cells, thereby reducing airway hyperreactivity and improving lung function in patients with severe allergic...